Sanofi says COVID-19 vaccine candidate yields positive trial data

COVID-19 vaccine candidate delivered 72% efficacy in adults against the Omicron strain

Sanofi's COVID-19 vaccine candidate delivered 72% efficacy in adults against the Omicron strain, the French drugmaker said on Friday, citing data gathered in a study, Qazet.az reports.

"Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," the firm, which is developing the vaccine jointly with Britain's GSK.

The new data supporting its booster vaccine will be submitted to regulatory authorities, Sanofi added, reiterating its plan to start marketing its jab later this year.